AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

NanoVibronix, Inc. Common Stock

$3.43 -$25.97 (-88.33%)
NASDAQ · 14 Sep 2026 19:59 UTC
Previous Close
$3.58
Day Range
$3.33$3.58
Year Range
$0.29$5.98
Market Cap
2.66M
AVG Volume
93.19K
Trailing/Forward PE
-0/-
PEG ratio
0
Dividend Yield
-
Next Earnings Date
2026-11-17
Primary Exchange
NASDAQUS
Revenue (USD) · TTM
01M2M3M4M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
FEED Revenue (USD) · TTM by quarter
PeriodRevenue (USD) · TTM
26 Q21.93M
26 Q12.18M
25 Q42.55M
25 Q32.69M
25 Q22.34M
25 Q12.66M
24 Q42.56M
24 Q33.29M
24 Q23.37M
24 Q12.85M
Net Income (USD) · TTM
-30M-20M-10M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
FEED Net Income (USD) · TTM by quarter
PeriodNet Income (USD) · TTM
26 Q2-20.97M
26 Q1-16.23M
25 Q4-14.9M
25 Q3-3.48M
25 Q2-5.08M
25 Q1-5.61M
24 Q4-3.71M
24 Q3-3.09M
24 Q2-2.82M
24 Q1-3.2M
Operating Income (USD) · TTM
-20M-15M-10M-5M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
FEED Operating Income (USD) · TTM by quarter
PeriodOperating Income (USD) · TTM
26 Q2-15.09M
26 Q1-13.59M
25 Q4-11.73M
25 Q3-9.45M
25 Q2-8.17M
25 Q1-4.87M
24 Q4-3.58M
24 Q3-2.91M
24 Q2-2.61M
24 Q1-2.95M
EBITDA (USD) · TTM
-15M-10M-5M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
FEED EBITDA (USD) · TTM by quarter
PeriodEBITDA (USD) · TTM
26 Q2-14.44M
26 Q1-12.59M
25 Q4-11.46M
25 Q3-6.38M
25 Q2-8.23M
25 Q1-5.51M
24 Q4-3.67M
24 Q3-2.95M
24 Q2-2.62M
24 Q1-2.95M
Cash Flows (USD) · TTM
-15M-10M-5M019 Q219 Q319 Q421 Q121 Q221 Q321 Q425 Q426 Q126 Q2
FEED Cash Flows (USD) · TTM by quarter
PeriodCash Flows (USD) · TTM
26 Q2-11.74M
26 Q1-12.41M
25 Q4-9.43M
21 Q4-4.37M
21 Q3-4.83M
21 Q2-4.89M
21 Q1-3.45M
19 Q4-3.87M
19 Q3-3.72M
19 Q2-3.41M
EPS (USD) · TTM
-100000-75000-50000-25000024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
FEED EPS (USD) · TTM by quarter
PeriodEPS (USD) · TTM
26 Q2-82757.16
26 Q1-82857
25 Q4-802.56
25 Q3-657.21
25 Q2-685.45
25 Q1-589.03
24 Q4-137.2
24 Q3-135.81
24 Q2-143.12
24 Q1-187.01
Expenses (USD) · TTM
05M10M15MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
FEED Expenses (USD) · TTM by quarter
PeriodExpenses (USD) · TTM
21 Q43K
21 Q35K
21 Q24K
21 Q14K
19 Q40
19 Q30
19 Q23K
26 Q214.69M
26 Q113.39M
25 Q411.95M
25 Q310.25M
25 Q28.92M
25 Q16.08M
24 Q45.09M
24 Q34.88M
24 Q24.79M
24 Q14.92M
Shares Outstanding (USD) · TTM
01M2M3M4M19 Q219 Q319 Q421 Q121 Q221 Q321 Q425 Q426 Q126 Q2
FEED Shares Outstanding (USD) · TTM by quarter
PeriodShares Outstanding (USD) · TTM
26 Q23.04M
26 Q11.56M
25 Q40
21 Q40
21 Q30
21 Q20
21 Q10
19 Q40
19 Q30
19 Q20
Free Cash Flow Yield
-1500000%-1000000%-500000%0%med -1087.87%Mar 26May 26Jun 26Jul 26Aug 26Sep 26
FEED Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-683.23%
Sep 26-639.33%
Sep 26-567.94%
Aug 26-1096923%
Aug 26-965947.12%
Aug 26-864559.54%
Aug 26-943810.83%
Jul 26-1195327.7%
Jul 26-989146.72%
Jul 26-907874.14%
Jul 26-714557.09%
Jul 26-726008.33%
Jun 26-655613.89%
Jun 26-562070.96%
Jun 26-455305.73%
Jun 26-434352.06%
May 26-1218.57%
May 26-1087.87%
May 26-998.86%
May 26-923.32%
May 26-923.32%
Apr 26-819.96%
Apr 26-695.41%
Apr 26-661.9%
Apr 26-560.59%
Mar 26-452.16%
Mar 26-915.62%
Mar 26-607.04%
Mar 26-546.64%
Price to Sales
00.511.5med 0.4Nov 25Jan 26Mar 26Apr 26Jun 26Jul 26Sep 26
FEED Price to Sales by quarter
PeriodPrice to Sales
Sep 260.89
Sep 260.95
Sep 261.07
Aug 260
Aug 260
Aug 260
Aug 260
Jul 260
Jul 260
Jul 260
Jul 260
Jul 260
Jun 260
Jun 260
Jun 260
Jun 260
May 260.3
May 260.34
May 260.37
May 260.4
May 260.4
Apr 260.45
Apr 260.53
Apr 260.56
Apr 260.66
Mar 260.82
Mar 260.4
Mar 260.61
Mar 260.68
Feb 260.67
Feb 260.88
Feb 260.9
Feb 260.93
Jan 261.03
Jan 260.35
Jan 260.42
Jan 260.74
Jan 260.78
Dec 250.82
Dec 250.96
Dec 251.31
Dec 251.33
Nov 250.09
Nov 250.08
Nov 250.09
Price to Book
00.030.050.080.1med 0.03Nov 25Jan 26Mar 26Apr 26Jun 26Jul 26Sep 26
FEED Price to Book by quarter
PeriodPrice to Book
Sep 260.06
Sep 260.06
Sep 260.07
Aug 260
Aug 260
Aug 260
Aug 260
Jul 260
Jul 260
Jul 260
Jul 260
Jul 260
Jun 260
Jun 260
Jun 260
Jun 260
May 260.02
May 260.03
May 260.03
May 260.03
May 260.03
Apr 260.03
Apr 260.04
Apr 260.04
Apr 260.05
Mar 260.06
Mar 260.03
Mar 260.05
Mar 260.05
Feb 260.04
Feb 260.06
Feb 260.06
Feb 260.06
Jan 260.07
Jan 260.02
Jan 260.03
Jan 260.05
Jan 260.05
Dec 250.05
Dec 250.06
Dec 250.08
Dec 250.08
Nov 250
Nov 250
Nov 250.01
NanoVibronix, Inc. Common Stock
FEED
Stockpicker

Video analysis: FEED

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: FEED

ENvue Medical Resumes U.S. Commercial Shipments of NanoVibronix PainShield® and Begins Fulfilling Open Distributor Orders

globenewswire.com · 9 Sep 2026

ENvue Medical Resumes U.S. Commercial Shipments of NanoVibronix PainShield® and Begins Fulfilling Open Distributor Orders

TYLER, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- ENvue Medical , Inc. (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement and therapeutic technologies, today announced that it has resumed commercial shipments of PainShield®, manufactured in the United States, and has begun fulfilling open orders from Ultra Pain Products, Inc. (“UPPI”), the Company's exclusive U.S. distribution partner for the product.

ENvue Medical Selected to Exhibit ENvue™ Navigation Platform at Vizient Innovative Technology Exchange

globenewswire.com · 2 Sep 2026

ENvue Medical Selected to Exhibit ENvue™ Navigation Platform at Vizient Innovative Technology Exchange

TYLER, Texas, Sept. 02, 2026 (GLOBE NEWSWIRE) -- ENvue Medical (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today announced it has been selected to exhibit its ENvue™ Navigation Platform, a minimally invasive electromagnetic navigation system guiding feeding tube placement, at the Vizient® Innovative Technology Exchange.

ENvue Medical Announces Exclusive UroShield® Distribution Agreement with Minimum Purchase Commitments of Approximately $2.6 Million

globenewswire.com · 18 Aug 2026

ENvue Medical Announces Exclusive UroShield® Distribution Agreement with Minimum Purchase Commitments of Approximately $2.6 Million

Multi-year agreement with Peak Medical expands UroShield commercialization across the United Kingdom and Republic of Ireland Multi-year agreement with Peak Medical expands UroShield commercialization across the United Kingdom and Republic of Ireland

ENvue Medical Secures Equity Financing Facility of Up to $50 Million to Support Commercial Growth, Technology Expansion and Strategic Acquisitions

globenewswire.com · 12 Aug 2026

ENvue Medical Secures Equity Financing Facility of Up to $50 Million to Support Commercial Growth, Technology Expansion and Strategic Acquisitions

TYLER, Texas, Aug. 12, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) ("ENvue" or the "Company"), a commercial-stage medical technology company, today announced that it has entered into a securities purchase agreement (“ELOC”) with an institutional investor providing the Company with an equity facility for up to $50 million in capital (the “Facility”), subject to the terms and conditions of the agreement, including the receipt of stockholder approval.

ENvue Medical Moves NanoVibronix Manufacturing to the United States, Consolidates R&D in Tel Aviv, Israel, Increasing Operational Efficiencies and Cost Reduction Opportunities

globenewswire.com · 4 Aug 2026

ENvue Medical Moves NanoVibronix Manufacturing to the United States, Consolidates R&D in Tel Aviv, Israel, Increasing Operational Efficiencies and Cost Reduction Opportunities

TYLER, Texas, Aug. 04, 2026 (GLOBE NEWSWIRE) -- ENvue Medical , Inc. (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical device company, today announced it has completed the transition of its NanoVibronix manufacturing operations from Israel to the United States, and consolidated its research and development operations in Tel Aviv, Israel, supporting the Company's broader initiative to reduce operating expenses and improve its cost structure. “Completing the transition of our NanoVibronix product line manufacturing to the United States marks the achievement of a major strategic operational initiative for the Company,” said Doron Besser, MD, CEO of ENvue Medical.

ENvue Medical Deploys Additional Navigation Platform with Existing Customer, A Leading North Texas Medical Center

globenewswire.com · 23 Jul 2026

ENvue Medical Deploys Additional Navigation Platform with Existing Customer, A Leading North Texas Medical Center

Additional Platform Deployment at Major Academic Medical Center Reflects Increasing Commercial Demand for Bedside Feeding Tube Navigation Additional Platform Deployment at Major Academic Medical Center Reflects Increasing Commercial Demand for Bedside Feeding Tube Navigation

ENvue Medical Appoints Chairman of the Board and New Directors, Bringing Clinical, AI Governance and Capital Markets Expertise to Navigation Platform

globenewswire.com · 15 Jul 2026

ENvue Medical Appoints Chairman of the Board and New Directors, Bringing Clinical, AI Governance and Capital Markets Expertise to Navigation Platform

Zeev Rotstein, M.D. Named Chairman Following Four Decades in Health System Leadership, Including 12 Years as Director General of Sheba Medical Center Zvi Joseph and Lior Buchman Join Board, Bringing Amdocs AI Governance Leadership and $320 Million in Executed Financings and M&A, Respectively TYLER, Texas, July 15, 2026 (GLOBE NEWSWIRE) -- ENvue Medical (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today announced that Zeev Rotstein, M.D.

Envue Medical Expands AI Navigation Platform With Robotic Prototype

benzinga.com · 9 Jul 2026

Envue Medical Expands AI Navigation Platform With Robotic Prototype

ENvue Medical, Inc. (NASDAQ:FEED) announced Thursday the development and demonstration of the prototype of ENvue Drive.

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.